The concept of engineering robust protein scaffolds for novel binding functions emerged 20
years ago, one decade after the advent of recombinant antibody technology. Early examples …

Highlights•A variety of albumin-binding moieties (ABMs) have been developed for half-life
extension of short-lived drugs.•Various drugs can incorporate a selected ABM for in situ HSA …

A genetically modified mouse is provided, wherein the mouse is incapable of rearranging
and expressing an endogenous mouse immunoglobulin light chain variable sequence …

The monospecific and bivalent characteristics of naturally occurring immunoglobulin G (IgG)
antibodies depend on homodimerization of the fragment crystallizable (Fc) regions of two …

The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …

2010-02-17 Assigned to MERUS BV reassignment MERUS BV ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PINTO, RUI …

Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy
chain immunoglobulin locus, a humanized light chain locus that expresses a universal light …

Given recent technological advances and advances in our understanding of cancer,
immunotherapy of cancer is being used with clear clinical benefit. The immunosuppression …

Described are transgenic, non-human animals comprising a nucleic acid encoding an
immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like …

US9145588B2 - Generation of binding molecules - Google Patents US9145588B2 - Generation
of binding molecules - Google Patents Generation of binding molecules Download PDF Info …